Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2103465 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Shining a spotlight on pulmonary hypertension associated with interstitial lung disease care: The latest advances in diagnosis and treatment.
J Manag Care Spec Pharm
January 2025
PRIME Education, New York City, NY.
Pulmonary hypertension associated with interstitial lung disease (PH-ILD) is a complex condition in which 2 consequential diseases interact and increase negative outcomes. Although the pathophysiologic mechanisms of PH-ILD are not yet well understood, the pronounced effect on functional status, supplemental oxygen requirements, health care resource utilization, and mortality that frequently accompany this diagnosis are well documented. A critical feature that complicates pathophysiologic understanding of PH-ILD is that progression of the pulmonary vascular disease does not always appear to be driven by the underlying lung disease.
View Article and Find Full Text PDFVasoreactivity and inhaled treprostinil response in interstitial lung disease pulmonary hypertension.
ERJ Open Res
November 2024
Brigham and Women's Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA, USA.
Introduction: Despite shared features with pulmonary arterial hypertension, acute vasoreactivity in pulmonary hypertension with interstitial lung disease (PH-ILD) is not well characterised, including its potential ability to predict therapeutic outcomes. We sought to determine whether acute vasoreactivity in PH-ILD to oxygen (O) and inhaled nitric oxide (iNO) predicts inhaled treprostinil (iTre) outcomes.
Materials And Methods: In this retrospective cohort analysis, we identified treatment-naive PH-ILD patients with vasoreactivity testing using O and O+iNO.
Treatment with Oral or Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities.
Chest
November 2024
University of Michigan, Ann Arbor, MI, USA. Electronic address:
Background: An increasing number of patients with pulmonary arterial hypertension (PAH) have cardiovascular comorbidities. However, the effects of comorbidities on responses to PAH treatment are not well understood.
Research Question: Do cardiovascular comorbidities in patients with PAH influence the efficacy and tolerability of inhaled or oral treprostinil?
Study Design And Methods: All patients from phase 3 studies TRIUMPH (N = 235) and FREEDOM-EV (N = 690) were included in this post hoc analysis and were classified as having 0, ≥1, or ≥2 cardiovascular comorbidities of interest based on patients' medical histories.
Inhaled epoprostenol via high-flow nasal cannula and intravenous treprostinil for management of severe pulmonary arterial hypertension during cesarean delivery with epidural anesthesia: a case report.
Int J Obstet Anesth
November 2024
TEAMHealth Anesthesia, United States; University of South Florida Department of Anesthesiology and Perioperative Medicine, United States. Electronic address:
Current guidelines for managing pulmonary arterial hypertension (PAH) in pregnancy recommend the use of PAH-specific medications, including phosphodiesterase type-5 inhibitors, calcium channel blockers, and prostacyclin analogs. However, there is limited consensus on the optimal agents and routes of administration during delivery. This case report describes a 24-year-old gravida 3 para 1 with Group I PAH, admitted at 29 weeks' gestation, for a planned cesarean delivery at 30 weeks gestation.
View Article and Find Full Text PDFEfficacy and determinants of response to inhaled treprostinil in pulmonary hypertension - interstitial lung disease.
Respir Med
November 2024
Division of Pulmonary Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, OH, United States.
Inhaled treprostinil has shown to improve exercise capacity in patients with pulmonary hypertension-interstitial lung disease (PH-ILD). We evaluated the efficacy and determinants of favorable response to inhaled treprostinil at six months. METHODS: Of the 106 patients screened, 42 were eligible for this retrospective single-center study.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!